Skip to content
10-Q

Quarterly Report

Sarepta Therapeutics, Inc. SRPT

0000950170-25-064412

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 2, 2025 98.28M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $281.9M
Short Term Investments Q1 2025 · Dec 31, 2024 $251.78M
Current Liabilities Q1 2025 · Mar 31, 2025 $605.59M
Current Liabilities Q1 2025 · Dec 31, 2024 $731.68M
Total Liabilities Q1 2025 · Mar 31, 2025 $2.32B
Total Liabilities Q1 2025 · Dec 31, 2024 $2.44B
Current Assets Q1 2025 · Mar 31, 2025 $2.43B
Current Assets Q1 2025 · Dec 31, 2024 $3.07B
Total Assets Q1 2025 · Mar 31, 2025 $3.47B
Total Assets Q1 2025 · Dec 31, 2024 $3.96B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $1.1B
Cash And Equivalents Q1 2025 · Mar 31, 2024 $427.29M
Shares Diluted Q1 2025 · Mar 31, 2024 99.11M sh
Capex Q1 2025 · Mar 31, 2024 $32.44M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$242.08M
Stockholders Equity Q1 2025 · Mar 31, 2024 $961.19M
Stockholders Equity Q1 2025 · Dec 31, 2023 $859.34M
Eps Diluted Q1 2025 · Mar 31, 2024 $0.37
Eps Basic Q1 2025 · Mar 31, 2024 $0.38
Sga Expense Q1 2025 · Mar 31, 2024 $127M
Net Income Q1 2025 · Mar 31, 2024 $36.12M
Operating Income Q1 2025 · Mar 31, 2024 $34.91M
Revenue Q1 2025 · Mar 31, 2024 $359.48M